RT Journal Article
SR Electronic
T1 Polygenic risk for Alzheimer’s disease predicts sleep slow-waves and daytime sleepiness in youth
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.02.26.20027912
DO 10.1101/2020.02.26.20027912
A1 Muto, Vincenzo
A1 Koshmanova, Ekaterina
A1 Ghaemmaghami, Pouya
A1 Jaspar, Mathieu
A1 Meyer, Christelle
A1 Elansary, Mahmoud
A1 Van Egroo, Maxime
A1 Chylinski, Daphne
A1 Berthomier, Christian
A1 Brandewinder, Marie
A1 Mouraux, Charlotte
A1 Schmidt, Christina
A1 Hammad, Grégory
A1 Coppieters, Wouter
A1 Ahariz, Naima
A1 Degueldre, Christian
A1 Luxen, André
A1 Salmon, Eric
A1 Phillips, Christophe
A1 Archer, Simon N.
A1 Yengo, Loic
A1 Byrne, Enda
A1 Collette, Fabienne
A1 Georges, Michel
A1 Dijk, Derk-Jan
A1 Maquet, Pierre
A1 Visscher, Peter M.
A1 Vandewalle, Gilles
YR 2020
UL http://medrxiv.org/content/early/2020/02/27/2020.02.26.20027912.abstract
AB A bidirectional detrimental relationship between sleep alteration and Alzheimer’s disease (AD) has been reported in cognitively normal older adults. Here, we tested whether a similar association could be detected in young adults, decades before typical AD symptom onset. We investigated associations between sleep endophenotypes and genome-wide Polygenic Risk Scores (PRS) for AD in 363 young men (22.1±2.7y) devoid of sleep and cognitive disorders. AD PRS was associated with higher slow wave energy, a marker of sleep need, during habitual sleep and following sleep loss, and, potentially, with the relative increase in slow wave energy following sleep deprivation, reflecting sleep homeostasis. Furthermore high AD PRS was correlated with higher daytime sleepiness. These results imply that sleep features may be associated with AD liability in young adults and suggest that, contrary to older adults, denser and/or more intense sleep slow waves are associated with AD risk in early adulthood.Competing Interest StatementThe authors have declared no competing interest.Funding StatementP.G., M.V., C.S., F.C., C.P. and G.V. are supported by the Fonds de la Recherche Scientifique - FNRS-Belgium. The study was supported by the Wallonia-Brussels Federation (Actions de Recherche Concertées - ARC - 09/14-03), WELBIO/Walloon Excellence in Life Sciences and Biotechnology Grant (WELBIO-CR-2010-06E), FNRS-Belgium (FRS-FNRS, F.4513.17 & T.0242.19 & 3.4516.11), University of Liège (ULiège), Fondation Simone et Pierre Clerdent, European Regional Development Fund (Radiomed project), Fonds Léon Fredericq. DJD is supported by the UK Dementia Research Institute (DRI).Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe authors declare that the data supporting the findings of this study are available from the corresponding author upon request.